#North America Cardiac Rhythm Management Procedures market

[marketsizereports]

Navigating the North American Cardiac Rhythm Management Procedures Market: Opportunities and Challenges

Navigating the North American cardiac rhythm management procedures market presents both opportunities and challenges for companies operating in this industry. Let's explore some of them:

Opportunities:

Growing Market Demand: The increasing prevalence of cardiac disorders and the aging population provide a significant opportunity for companies in the cardiac rhythm management market. As the demand for procedures such as pacemaker implantation, ICD placement, and cardiac ablation continues to rise, there is a larger market to cater to.

Technological Advancements: The continuous advancement of cardiac rhythm management technologies opens up opportunities for innovation and differentiation. Companies that develop and introduce novel devices, such as leadless pacemakers, subcutaneous ICDs, and advanced ablation systems, can gain a competitive edge and capture a larger market share.

Emerging Markets: Expanding into emerging markets within North America, such as Mexico and Canada, presents growth opportunities for companies. These markets may have increasing healthcare infrastructure, rising healthcare expenditure, and a growing patient population in need of cardiac rhythm management procedures.

Remote Monitoring and Telemedicine: The adoption of remote monitoring and telemedicine technologies in the cardiac rhythm management field provides opportunities for companies to enhance patient care and improve efficiency. Developing remote monitoring platforms and integrated telemedicine solutions can improve patient outcomes and reduce healthcare costs.

Collaborations and Partnerships: Collaborating with healthcare providers, research institutions, and technology companies can lead to valuable partnerships and synergies. Joint research and development initiatives, clinical trials, and market collaborations can help companies accelerate product development, gain access to new markets, and strengthen their position in the industry.

Challenges:

Competitive Market Landscape: The cardiac rhythm management market in North America is highly competitive, with established players and new entrants vying for market share. Companies face the challenge of differentiating their products and services in a crowded market and demonstrating superior clinical outcomes and patient benefits.

Stringent Regulatory Environment: The regulatory requirements for cardiac rhythm management devices and procedures are stringent to ensure patient safety. Obtaining regulatory approvals, meeting compliance standards, and keeping up with evolving regulations can be time-consuming and costly for companies.

Reimbursement and Pricing Pressures: Reimbursement policies and negotiations with payers pose challenges in the market. Companies must navigate the reimbursement landscape to ensure adequate coverage and appropriate pricing for their products. Reimbursement challenges can impact market access and financial viability.

Evolving Healthcare Policies: Changes in healthcare policies, including shifts towards value-based care and alternative payment models, can impact the market dynamics. Companies need to adapt to evolving policies and demonstrate the value and cost-effectiveness of their products and procedures to secure market adoption.

Physician Adoption and Training: The successful adoption of cardiac rhythm management procedures depends on physicians' skills, knowledge, and comfort with new technologies. Companies may face challenges in training healthcare professionals, ensuring consistent adoption practices, and addressing any resistance to change.

Data Security and Privacy: The increasing use of digital health technologies and connected devices in cardiac rhythm management raises concerns about data security and patient privacy. Companies must invest in robust cybersecurity measures and comply with data protection regulations to maintain patient trust and safeguard sensitive health information.

Economic Factors: Economic fluctuations, healthcare budget constraints, and cost containment efforts can influence market dynamics. Companies need to navigate these economic factors and demonstrate the value and cost-effectiveness of their products to withstand market challenges.

For more insights on the North America CRM Procedures market category analysis, download a free report sample

Navigating the North American cardiac rhythm management procedures market requires a thorough understanding of the opportunities and challenges, along with a strategic approach to product development, market access, partnerships, and regulatory compliance. Adapting to evolving market dynamics and customer needs is crucial for success in this competitive landscape.

[global-research-report]

Revolutionizing Cardiac Procedures: The Expanding Market for Electrophysiology Devices

The global electrophysiology (EP) devices market was valued at USD 12.9 billion in 2024 and is expected to experience robust growth, with a projected compound annual growth rate (CAGR) of 15.1% from 2025 to 2030. Several key factors are driving this growth, including the increasing use of electrophysiology tests for the diagnosis and treatment of heart diseases, particularly atrial fibrillation. There is also a rising demand for cardiac rhythm management devices to provide continuous monitoring of heart function. Additionally, the expanding use of electrophysiology devices in out-of-hospital settings, such as home care or remote patient monitoring, is further propelling market growth.

The prevalence of heart diseases, including heart failure, cardiac arrest, and atrial fibrillation, is rising, particularly among younger populations such as millennials. Sedentary lifestyles, smoking, excessive alcohol consumption, and poor dietary habits are contributing to this trend. According to data from the Centers for Disease Control and Prevention (CDC), the number of Americans suffering from atrial fibrillation is expected to reach approximately 12.1 million by 2030. This growing burden of heart disease is driving the demand for advanced electrophysiology devices aimed at improving diagnosis, treatment, and long-term management.

Another key factor supporting the market's expansion is the increasing number of catheter ablation procedures, a common treatment for conditions like atrial fibrillation. As the number of these procedures rises, there is a direct increase in the demand for ancillary products, including catheters, ablation tools, and other supportive devices used during these procedures. The market is also being boosted by advancements in the functionality of electrophysiology devices. Modern EP devices are designed to improve maneuverability for navigating complex anatomies, flexibility for accessing targeted heart areas, and compatibility with a wider range of clinical applications. Additionally, many EP devices now incorporate integrated imaging capabilities that enhance the visualization of the heart during diagnostic and therapeutic procedures, making them more precise and effective.

For example, according to an article published by Elsevier Inc. in March 2023, the annual rate of cardiac electrophysiology procedures in the U.S. increased significantly from 817.9 procedures per 100,000 beneficiaries in 2013 to 1,089.68 per 100,000 beneficiaries in 2019. This data highlights the growing reliance on electrophysiology procedures to diagnose and treat heart conditions, further reinforcing the positive outlook for the EP devices market.

Regional Insights

North America:

The North American electrophysiology devices market is the largest globally, commanding 49.45% of the total revenue share in 2024. This dominant position is largely driven by the rising incidence of cardiovascular diseases, including conditions like atrial fibrillation, and the advanced healthcare infrastructure in the region. The presence of several key market players and ongoing technological innovations in electrophysiology devices further fuel the market's growth. Additionally, the growing number of patients undergoing minimally invasive surgeries, such as catheter ablation procedures, is contributing to increased demand for EP devices. Increased awareness among patients and healthcare providers about the benefits of minimally invasive procedures is also a significant factor in driving market expansion in North America.

United States:

 In the United States, the electrophysiology devices market holds over 85.0% of the revenue share in 2024, and is expected to grow at the fastest CAGR during the forecast period. The rapid adoption of advanced healthcare technologies, a growing patient population, and the rising number of new product launches in the EP device market are key factors contributing to this rapid growth. The increasing demand for effective treatment options for heart diseases and the widespread use of EP devices in both hospital settings and outpatient care are expected to further propel market growth in the U.S. in the coming years.

Europe:

 The Europe electrophysiology devices market is the second-largest globally, holding a significant revenue share in 2024. Europe is home to a robust healthcare system, with a noticeable shift from traditional in-patient care to out-patient care. This shift is driven by the growing presence of medical equipment companies offering specialized products like catheters for electrophysiology procedures. The Germany electrophysiology devices market accounted for the largest revenue share in Europe at 27.8% in 2024. The increasing prevalence of cardiac disorders, particularly coronary artery disease, is expected to drive greater demand for catheters used in treating narrowed arteries in patients.

UK:

The UK held the third-largest market share in Europe in 2024. The rising prevalence of cardiovascular diseases, including coronary artery disease and ischemic heart disease, is expected to boost the demand for electrophysiology devices, especially as the healthcare system focuses more on early diagnosis and minimally invasive treatment options.

France:

In France, the market is projected to witness a significant CAGR of 13.9% during the forecast period. This growth is attributed to the increasing incidence of cardiovascular diseases, a growing number of hospitals and clinics offering advanced heart disease treatments, and lifestyle changes in the population, which are contributing to higher rates of heart-related conditions.

Asia Pacific:

The Asia Pacific electrophysiology devices market is projected to grow at the fastest CAGR of 14.8% during the forecast period, driven by a combination of factors, including increased health awareness, a rapidly developing private hospital sector, growing government support and spending on healthcare, and a rising prevalence of cardiovascular diseases. Additionally, the expanding availability of insurance policies in the region is expected to drive further growth.

China:

In China, the electrophysiology devices market held the largest revenue share at 32.3% in 2024. This is due to the increasing prevalence of cardiovascular diseases caused by factors such as high blood pressure, unhealthy lifestyles, an aging population, urbanization, and high cholesterol levels. These health challenges are anticipated to significantly boost demand for EP devices in China in the coming years.

Japan:

Japan holds the second-largest market share in Asia Pacific. The country faces a high burden of cardiovascular disorders, including atrial fibrillation and stroke, which have a considerable impact on life expectancy and healthcare costs. With the growing prevalence of heart diseases, Japan's demand for electrophysiology devices is expected to rise substantially.

India:

India is projected to grow at the fastest CAGR of 16.1% in Asia Pacific. The increasing prevalence of coronary artery disease is expected to drive the demand for interventional ablation procedures, which in turn will stimulate the market for EP devices. Additionally, the growing number of private hospitals and government-run healthcare facilities providing cardiovascular disease treatments will contribute to significant market growth in the country.

Latin America:

electrophysiology devices market is expected to grow at the fastest CAGR in the region during the forecast period. Cardiovascular disease (CVD) remains one of the leading causes of death across Latin American countries, with atrial fibrillation (AFib) being one of the top four cardiovascular conditions in the region. The increasing incidence of heart diseases and the subsequent demand for innovative EP devices to manage and treat these conditions will drive growth.

Mexico:

In Mexico, the electrophysiology devices market is expected to experience significant growth during the forecast period. Factors contributing to this growth include the high incidence of chronic heart diseases, improved medical facilities, and favorable regulatory policies. According to a Johnson & Johnson article, atrial fibrillation affects nearly 417,000 people in Mexico, which underscores the growing need for electrophysiology devices in the country.

Middle East & Africa:

The Middle East & Africa electrophysiology devices market is expected to experience strong growth during the forecast period. This region is becoming a significant developing market for medical devices, fueled by the rising prevalence of ischemic heart disease, vascular disease, and coronary artery disease. The increasing awareness among the public about the importance of early diagnosis and the use of advanced devices is also expected to contribute to the market's growth.

South Africa:

In South Africa, the electrophysiology devices market held the largest revenue share in 2024, accounting for 22.5% of the total market in the region. Technological advancements in healthcare delivery are significantly improving access to treatment across Africa, and South Africa serves as a key hub for ablation procedures in the region. This has positioned South Africa as a leader in the electrophysiology devices market in Africa.

Browse through Grand View Research's Category Medical Devices Industry Research Reports.

The global topical scar treatment market sizewas estimated at USD 1.69 billion in 2024 and is expected to grow at a CAGR of 11.9% from 2025 to 2030.

The global demineralized bone matrix market sizewas estimated at USD 1.24 billion in 2024 and is projected to grow at a CAGR of 5.9% from 2025 to 2030.

Key Electrophysiology Devices Companies:

The following are the leading companies in the electrophysiology devices market. These companies collectively hold the largest market share and dictate industry trends.

Boston Scientific Corp.

Medtronic

Abbott

Biosense Webster (Johnson & Johnson Services, Inc.)

Biotronik

General Electric Company

Siemens Healthcare AG

MicroPort Scientific Corporation

Koninklijke Philips N.V.

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.

[priteshwemarketresearch]

Cardiovascular Devices Market 2024 Analysis Key Trends, Growth Opportunities, Challenges, Key Players, End User Demand and Forecasts to 2034

Cardiovascular Devices Market: Trends, Growth, and Future Outlook

The cardiovascular devices market is a vital segment of the global medical device industry, driven by the increasing prevalence of heart diseases, advancements in medical technology, and rising demand for minimally invasive procedures. Cardiovascular devices, which include a range of tools and equipment used to diagnose, monitor, and treat cardiovascular conditions, are essential in the management of heart-related health issues. As the global burden of cardiovascular diseases (CVD) continues to rise, the market for these devices is expanding rapidly. This blog explores the key trends, growth drivers, challenges, and future prospects of the cardiovascular devices market.

Request Sample Copy:

https://wemarketresearch.com/reports/request-free-sample-pdf/cardiovascular-devices-market/361

What Are Cardiovascular Devices?

Cardiovascular devices are medical instruments designed for the treatment and management of heart-related diseases. They include a wide range of devices, such as:

Cardiac Pacemakers – Devices implanted in the chest to regulate heartbeats.

Stents – Small mesh tubes used to treat narrowed or blocked arteries.

Heart Valve Devices – Implants designed to replace or repair damaged heart valves.

ECGs/EKGs – Devices that monitor electrical activity of the heart.

Ablation Catheters – Used for treating abnormal heart rhythms.

Implantable Cardioverter Defibrillators (ICDs) – Devices that monitor heart rhythms and can deliver shocks if necessary.

Vascular Devices – Tools used to treat diseases in veins and arteries, such as angioplasty balloons and guidewires.

These devices play a crucial role in the diagnosis, monitoring, and treatment of cardiovascular diseases, including coronary artery disease, heart failure, arrhythmias, and peripheral vascular diseases.

Key Drivers of the Cardiovascular Devices Market

The growth of the cardiovascular devices market is being driven by several factors, including:

Increasing Prevalence of Cardiovascular Diseases

Cardiovascular diseases remain the leading cause of death worldwide. According to the World Health Organization (WHO), CVDs account for nearly 31% of global deaths each year. As the aging population grows and lifestyle-related risk factors such as obesity, smoking, and physical inactivity become more prevalent, the demand for effective cardiovascular treatments and monitoring solutions continues to rise.

Technological Advancements

Recent technological innovations have transformed the cardiovascular devices market. For instance, the development of minimally invasive procedures and robotic-assisted surgeries has improved the effectiveness of treatments while reducing recovery times and associated risks. Moreover, advancements in 3D printing, biosensors, and artificial intelligence are contributing to the development of more sophisticated, precise, and personalized cardiovascular devices.

The introduction of bioresorbable stents, which gradually dissolve after they have fulfilled their purpose, and smart pacemakers, which offer remote monitoring capabilities, exemplifies how technology is reshaping the market.

Rising Geriatric Population

The global geriatric population is growing rapidly. As people age, the risk of developing cardiovascular diseases increases. According to the United Nations, by 2050, one in six people in the world will be aged 60 years or older. This demographic shift is expected to increase the demand for cardiovascular devices, as older adults are more likely to require treatments such as stent placement, heart valve repair or replacement, and pacemaker implantation.

Increased Healthcare Expenditure

Many countries, especially in North America and Europe, are increasing their healthcare budgets to address the rising prevalence of chronic diseases like CVDs. Government initiatives and insurance coverage expansion are further contributing to the accessibility of cardiovascular treatments, which is driving demand for cardiovascular devices.

Growing Awareness and Preventive Healthcare

There is an increasing focus on preventive healthcare and early diagnosis of heart diseases. People are more aware of the risks associated with cardiovascular diseases and are seeking regular check-ups, diagnostic tests, and treatments. This growing awareness and shift toward early detection are fueling demand for cardiovascular diagnostic devices like ECG monitors, echocardiograms, and blood pressure monitoring devices.

Key Trends in the Cardiovascular Devices Market

Several trends are shaping the cardiovascular devices market:

Shift Toward Minimally Invasive Procedures

Minimally invasive cardiovascular procedures, such as catheter-based interventions, robotic surgeries, and endovascular treatments, are gaining popularity due to their benefits of reduced recovery time, lower infection risk, and shorter hospital stays. This trend is leading to a higher adoption of advanced cardiovascular devices, especially stents, catheters, and balloon angioplasty systems.

Integration of Wearable Devices

Wearable cardiovascular devices that monitor heart activity in real-time are on the rise. These devices, including wearable ECG monitors, fitness trackers, and smartwatches that track heart rate and rhythms, allow individuals to continuously monitor their heart health and detect potential issues early. The integration of these devices with mobile apps and cloud-based systems is also enabling remote monitoring by healthcare providers, improving patient care and outcomes.

Growth of the Asia-Pacific Market

The Asia-Pacific (APAC) region is becoming an increasingly important market for cardiovascular devices. With improving healthcare infrastructure, a growing middle class, and rising healthcare awareness, countries such as China, India, and Japan are witnessing a surge in demand for cardiovascular treatments and devices. This region is expected to show strong growth in the coming years, offering significant opportunities for manufacturers.

Regulatory Developments

Regulations surrounding the approval and sale of cardiovascular devices are becoming more stringent. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are setting higher standards for device safety and efficacy. While these regulations may slow the time to market for new devices, they ultimately ensure that the products are of high quality and reliability.

Challenges Facing the Cardiovascular Devices Market

Despite its rapid growth, the cardiovascular devices market faces some challenges:

High Cost of Devices and Procedures

The cost of advanced cardiovascular devices, such as heart valves, pacemakers, and stents, can be prohibitively expensive for both healthcare providers and patients, especially in low-income regions. This price barrier could limit market expansion in certain parts of the world.

Reimbursement Issues

In some countries, reimbursement policies for cardiovascular procedures and devices are complex and vary widely. Insufficient reimbursement or changes in reimbursement rates can discourage healthcare providers from adopting new devices or procedures, limiting the growth of the market.

Safety and Complications

Although cardiovascular devices are essential for treating heart conditions, there are inherent risks, such as device malfunctions, infections, and complications following implantation. Manufacturers must invest in research and development to enhance device safety, reduce complications, and improve patient outcomes.

Future Outlook for the Cardiovascular Devices Market

The cardiovascular devices market is poised for substantial growth. Technological innovations, expanding healthcare access, and increasing global awareness about cardiovascular health will continue to drive demand for these devices. The shift toward minimally invasive procedures, along with advancements in wearable and diagnostic technologies, will open up new avenues for growth.

In the coming years, the market is likely to see a further increase in the adoption of smart technologies in cardiovascular care, including remote monitoring and AI-assisted diagnostics. Additionally, emerging markets in the Asia-Pacific region are expected to provide significant growth opportunities, particularly with the rise of middle-class populations and expanding healthcare systems.

Conclusion

The cardiovascular devices market is experiencing rapid growth driven by technological innovation, a rising prevalence of heart disease, and an aging global population. While there are challenges to overcome, including high device costs and regulatory hurdles, the future looks bright as new technologies continue to improve patient outcomes and make cardiovascular care more accessible worldwide. Companies that invest in research, focus on innovation, and adapt to changing market trends will be well-positioned to thrive in this dynamic and growing market.

[blog-site-for-market-research]

Forecasting the Size of Long QT Syndrome Market

Market Overview –

The long QT syndrome market is anticipated to grow at a 5.2% CAGR from 2022 to 2030, or USD 3,933.02 million.

The Long QT Syndrome (LQTS) market encompasses medical interventions and devices designed to diagnose, treat, and manage this cardiac disorder characterized by abnormal heart rhythms. LQTS increases the risk of sudden cardiac arrest or arrhythmias, posing serious health threats. The market includes genetic testing, medications, implantable cardioverter-defibrillators (ICDs), and lifestyle modifications aimed at reducing the risk of life-threatening events.

The Long QT Syndrome market is characterized by advancements in understanding and managing this cardiac disorder. With a focus on long QT disorder, healthcare providers emphasize early diagnosis and personalized treatment approaches to mitigate the risk of life-threatening arrhythmias. As awareness grows, there's a rising demand for innovative therapies and genetic testing, driving market growth and research endeavors.

A key driver of the Long QT Syndrome market is the growing awareness of inherited cardiac disorders and advances in genetic testing technology. Early detection through genetic screening allows for timely interventions, such as medication adjustments or implantation of ICDs, to prevent cardiac events and improve patient outcomes.

Advancements in medical devices, such as miniaturized ICDs and wearable cardiac monitors, have revolutionized the management of Long QT Syndrome. These devices provide continuous monitoring and early detection of arrhythmias, offering peace of mind to patients and caregivers while improving overall safety.

The COVID-19 pandemic has impacted the Long QT Syndrome market, with disruptions in routine medical care, delayed diagnoses, and challenges in accessing specialized cardiac services. However, telemedicine and remote monitoring technologies have emerged as valuable tools in managing Long QT Syndrome, enabling patients to receive timely care and support from healthcare providers.

Segmentation –

The global long QT syndrome market is segmented on the basis of type, diagnosis, treatment, and end users. On the basis of the type, the market is segmented into long QT syndrome type 1, long QT syndrome type 2, long QT syndrome type 3, and others.  On the basis of the diagnosis, the market is categorized into tests, electrocardiogram (ECG), genetic testing, and others.

On the basis of the treatment, the market is segmented into medication, surgical procedures, and others.  On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic labs, research organizations, and others.

Regional Analysis –

Regional analysis of the Long QT Syndrome (LQTS) market reveals variations in diagnosis rates, treatment options, and healthcare infrastructure across different regions. In developed regions like North America and Europe, where there is greater awareness of genetic disorders and access to specialized cardiac care, the market for LQTS diagnostics and management is well-established, with genetic testing, beta-blockers, and implantable cardioverter-defibrillators (ICDs) being standard of care.

Conversely, in developing regions with limited access to advanced cardiac diagnostics and therapies, such as parts of Africa and Asia-Pacific, the market for LQTS is still emerging, with challenges related to underdiagnosis and limited treatment options. Moreover, cultural attitudes towards genetic testing and preventive healthcare influence patient behaviors and healthcare-seeking patterns across different regions. As awareness of LQTS and its genetic basis increases globally, there is a growing opportunity for market expansion through education, advocacy, and investment in cardiac care infrastructure to improve outcomes for LQTS patients worldwide.

Key Players –

Long QT syndrome key players include Invitae Corporation (U.S.), GeneDx (U.S.), Asper Biogene (Estonia), Boston Scientific Corporation (U.S.), Laboratory Corporation of America Holdings (U.S.), Pfizer Inc. (U.S.), Zydus Pharmaceuticals, Inc. (U.S.), Aralez Pharmaceuticals Inc. (Canada), AstraZeneca (U.K.), Torrent Pharmaceuticals Limited (India), Lupin Pharmaceuticals, Inc. (U.S.), Cipla Inc. (India), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), and others.

Related Reports –

Pain Patch

Electronic Trial Master File Systems

Neurology Devices

Medical Payment Fraud Detection

For more information visit at MarketResearchFuture

[mrfr-blogs]

Analyzing the Size and Scope of Paroxysmal Supraventricular Tachycardia Market Industry

Market Overview –

The Paroxysmal Supraventricular Tachycardia (PSVT) market is estimated to record USD 490 million at a CAGR of around 6.90% during the forecast period, 2023-2030.

The Paroxysmal Supraventricular Tachycardia (PSVT) Market is growing due to the increasing prevalence of PSVT disease. This condition involves sudden episodes of rapid heart rate originating from the upper chambers of the heart. Treatment options include medications to control heart rhythm and procedures such as ablation therapy. The market offers a range of pharmaceuticals and interventions to manage PSVT and improve patients' cardiac health.

The paroxysmal supraventricular tachycardia (PSVT) market is experiencing growth driven by increasing incidences of this cardiac arrhythmia and advancements in diagnostic technologies and treatment options. PSVT is characterized by episodes of rapid heart rate originating from the upper chambers of the heart, leading to symptoms such as palpitations, chest discomfort, and dizziness.

Factors such as aging populations, underlying heart conditions, and lifestyle factors contribute to the prevalence of PSVT. Key drivers of market growth include the development of catheter ablation techniques, antiarrhythmic medications, and implantable devices for managing PSVT.

Moreover, the integration of remote monitoring and telemedicine solutions is improving the management of PSVT and enhancing patient outcomes. However, challenges such as misdiagnosis, recurrence of arrhythmias, and the need for specialized cardiac care facilities remain concerns for patients and healthcare providers. Overall, the PSVT market is poised for further expansion as research efforts focus on improving treatment efficacy and reducing the burden of arrhythmia-related complications.

Segmentation –

The Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal atrial tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).

On the basis of diagnosis, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.

On the basis of treatment, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. Antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.

On the basis of end-user, the global Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.

Regional Analysis –

The market for paroxysmal supraventricular tachycardia (PSVT) treatments shows regional variations influenced by factors such as healthcare infrastructure, prevalence rates, and access to treatment options. North America dominates the market, driven by a high prevalence of PSVT cases and advanced healthcare facilities for diagnosis and treatment.

Europe follows suit, with countries like the UK, Germany, and France investing in cardiac care infrastructure and research initiatives. In the Asia Pacific region, increasing awareness about cardiovascular health and improving access to healthcare services contribute to market growth, particularly in countries like China and India.

Latin America and the Middle East & Africa regions also show potential for market expansion, albeit with challenges related to healthcare access and affordability. Overall, the regional analysis underscores the need for comprehensive healthcare strategies to address the diverse needs of patients with PSVT across different regions.

Key Players –

Paroxysmal Supraventricular Tachycardia (PSVT) prominent players are GlaxoSmithKline PLC headquartered in the U.K., Novartis AG based in Switzerland, Pfizer, Inc. from the U.S., AstraZeneca PLC headquartered in the U.K., Teva Pharmaceutical Industries based in Israel, Sanofi SA from France, Medtronic, Inc. headquartered in the U.S., Glenmark Pharmaceuticals also based in the U.S., St. Jude Medical, Inc. from the U.S., BIOTRONIK SE & Co. KG based in the U.S., GE Healthcare headquartered in the U.S., Boston Scientific Corporation from the U.S., Abbott Laboratories Inc. headquartered in the U.S., Novartis (Alcon) based in the U.S., Siemens AG from Germany, Koninklijke Philips N.V. headquartered in the U.S., along with other participants.

Related Reports –

Anticoagulation

Heart Failure POC and LOC Devices

Cellulite Treatment

Epilepsy Devices

For more information visit at MarketResearchFuture

[alicesara611]

Wired for Success: Key Insights into the Electrophysiology Device Market by 2030

The global electrophysiology (EP) device market is expected to grow at a compound annual growth rate (CAGR) of 11.16% from 2023 to 2030 to reach US$ 13.9 billion by 2030. This growth is being driven by factors such as the increasing prevalence of cardiac arrhythmias, the growing demand for minimally invasive treatment options, and the aging population.

The driving forces behind this surge are the increasing adoption of Electrophysiology (EP) tests in heart disease treatment and diagnosis, particularly in addressing conditions like atrial fibrillation. The growing demand for devices dedicated to cardiac rhythm management for continuous monitoring and their expanding applications in out-of-hospital settings are key contributors to this industry growth.

Request a Sample copy of this Report! https://absolutemarketresearch.com/Global-Electrophysiology-(EP)-Device-Market/1245/request-sample

A notable trend supporting this expansion is the rising prevalence of heart failure, cardiac arrest, and atrial fibrillation among millennials. Lifestyle factors such as sedentary habits, smoking, excessive alcohol consumption, and others are contributing to this concerning health landscape. According to the Centers for Disease Control and Prevention (CDC), it is estimated that approximately 12.1 million Americans will be afflicted by atrial fibrillation by 2030.

The market growth is indicative of the increasing reliance on electrophysiology devices for comprehensive cardiac care, reflecting a paradigm shift in healthcare practices. The constant evolution of medical technology, coupled with the imperative need for precise and efficient diagnosis and treatment methods, has positioned electrophysiology devices as integral components of modern healthcare infrastructure.

Future Outlook:

The electrophysiology devices market is expected to continue to grow in the coming years, driven by the factors mentioned above. The increasing prevalence of heart diseases, the growing demand for minimally invasive procedures, and the rising adoption of electrophysiology devices in out-of-hospital settings are all expected to contribute to the market growth. The market is also expected to be driven by the development of new technologies, such as robotic-assisted surgery and 3D mapping systems.

Key Takeaways:

The global electrophysiology devices market is expected to reach US$ 13.9 billion by 2030, growing at a CAGR of 11.16% from 2023 to 2030.

The increasing use of electrophysiology (EP) tests in the diagnosis and treatment of heart diseases, such as atrial fibrillation, is driving the growth of the market.

The growing demand for devices for cardiac rhythm management for constant monitoring is also contributing to the market growth.

The increasing application of these devices in out-of-hospital settings is further propelling the industry growth.

Region Outlook:

North America is expected to be the largest market for electrophysiology devices, accounting for over 40% of the global market share in 2023.

The high prevalence of heart diseases and the well-developed healthcare infrastructure in North America are driving the growth of the market in this region.

Europe is expected to be the second largest market for electrophysiology devices, followed by Asia Pacific.

The growing demand for minimally invasive procedures in Europe is driving the growth of the market in this region.

The rising prevalence of heart diseases in Asia Pacific is also contributing to the market growth in this region.

Key Players:

Abbott Laboratories

Boston Scientific Corporation

Medtronic plc

Siemens Healthineers AG

Johnson & Johnson

Biotronik SE & Co. KG

LivaNova PLC

St. Jude Medical, Inc.

Olympus Corporation

Asahi Kasei Corporation

Segmentation:

By Type:

Electrophysiology Lab Devices

Diagnostic EP Catheters

Cardiac Ablation Catheters

By Application:

Hospital

Clinic

By End User:

Hospitals

Clinics

Ambulatory Surgical Centers

[desaletushki]

Cardiac Rhythm Management Devices Market Growth USD31.9 Billion By 2030

The global cardiac rhythm management devices market size is anticipated to reach USD 31.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 6.5% from 2022 to 2030. The key factors driving the market include growth in the adoption of cardiac rhythm management (CRM) devices owing to the increasing prevalence of cardiovascular disorders. According to the Centers for Disease Control and Prevention (CDC), as of September 2021, approximately 659,000 Americans die suffering from heart disease every year. The market was negatively impacted during the COVID-19 pandemic, as elective procedures, including the non-essential cardiovascular procedures, were postponed or canceled during the pandemic.

Major players in the market such as Medtronic; Abbott; and Boston Scientific Corporation, incurred huge losses in their cardiac rhythm management business segments globally. This resulted in negative growth of the market in 2020. The rising demand for handling sudden cardiac arrests is leading to innovation in all types of cardiac rhythm management devices. Innovation with regards to implantable devices includes products, such as subcutaneous and transvenous devices, that aim to increase the comfort level of patients. Swedish Transport Agency ran a program under the test phase, which aimed to deliver AEDs using a drone. This may reduce the delivery time of an AED, increasing the chances of survival with faster treatment.

Therefore, the market is anticipated to grow because of technological advancements and product innovations. Revolutionary technological signs of progress are rapidly transforming the market. These expansions are producing lucrative potentials. An increase in R&D expenditure and new product launches by leading firms further fueled the growth. For instance, in October 2020, Abbott launched its new ICD and CRT-D in India, hence expanding its product portfolio in the country. The company had also received CE Mark approval for its Gallant ICD and CRT-D devices in February 2020. Such factors boost market growth. Key market players account for a significant share of the market owing to their extensive product offerings.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/cardiac-rhythm-management-devices-industry

Cardiac Rhythm Management Devices Market Report Growth And Trends

The market was valued at USD 18.1 million in 2021 and is expected to expand at a CAGR of 6.5% during the forecast period

By product, defibrillators dominated the market with a share of over 43.6% in 2021 due to their high adoption globally

The ICD segment was the largest in defibrillators as of 2021, accounting for more than 60% of the revenue share, owing to its better patient outcome

In the external defibrillator segment, the automatic external defibrillator segment held the highest revenue share owing to associated benefits, including pacing, i.e., delivering pulses of the current to stimulate heart contraction as well as cardioversion, converting arrhythmia or tachycardia to a normal heartbeat

In 2021, North America held the dominant share of the market owing to the rising prevalence of cardiovascular diseases and high adoption of CRM devices

Asia Pacific region is expected to show lucrative growth over the forecast period owing to the presence of emerging countries such as China and India 

Cardiac Rhythm Management Devices Market Share Insights

The industry is marked by the presence of various large and small business operators. It is competitive and dominated by participants such as Medtronic, Abbott, Boston Scientific Corporation, and Koninklijke Philips N.V. Key players are focusing on executing innovative strategies like mergers and acquisitions, market penetration, partnerships, and distribution agreements to intensify their revenue. For instance, in July 2020, Abbott received the U.S. Food and Drug Administration (FDA) clearance for its Gallant ICD and CRT-D devices. This enabled the company to market the device in the U.S. while expanding its portfolio. Some of the prominent players in the cardiac rhythm management devices market include: Physio-Control Inc. (Stryker), Schiller, Medtronic, Abbott, Boston Scientific Corporation, Koninklijke Philips N.V., Zoll Medical Corporation, BIOTRONIK, Progetti Srl, LivaNova Plc

Request Free Sample Report: https://www.grandviewresearch.com/industry-analysis/cardiac-rhythm-management-devices-industry

[enchantingvoid]

Surgical Procedures Volume Market Analysis Growth Factors and Dynamic Demand by 2030

Global Surgical Procedures Volume Market: Snapshot

Surgical care is one of the most essential courses of actions required to effectively manage a variety of health conditions including obstructed labor, injuries, malignancy, cardiovascular disease and infections. Surgical care also forms one of the most important components of an effective and functioning healthcare system. International healthcare related organizations such as the World Health Organization (WHO) continue to underline surgery as one of the most essential components necessary for the overall development of the healthcare sector on a global front. However, improvement in surgical care requires the effective synchronization infrastructure, specialized supplies, and skilled human resources.

Download PDF Brochure: https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1718

As the economies of low- and middle-income countries develop at a steady pace and the basic public health scenario becomes better, injuries and chronic diseases are becoming some of the biggest challenges ahead of these countries, making up a big portion of the overall disease burden. To manage the conditions, investment in healthcare systems have also steadily increased in countries with steady economic growth and the volumes of surgical procedures have started significantly rising. Volumes of surgical procedures have also continued to rise at a massive pace in countries with developed economies in the past few years, with a significant share of all surgical procedures to have recorded in a particular year globally to have taken place in high-income countries across regions such as North America and Europe.

Global Surgical Procedures Volume Market: Overview 

Surgical procedures volume takes into account various kinds of procedures such as dental, urology, gynecology, ophthalmic, neurosurgery, orthopedic, and cardiovascular, which could be further classified into different categories. The future of surgical procedures lies in the advancement of technology on the part of minimally-invasive procedures and inclusion of robotics in surgical treatments. Presently used for gynecological procedures and gall bladder removal, single-incision laparoscopic surgery (SILS) is a highly advanced minimally-invasive surgery. 

Global Surgical Procedures Volume Market: Key Trends 

The international surgical procedures volume market is projected to witness a significant growth rate on the back of key factors such as increasing obese population, growing sedentary lifestyle causing elevating occurrences of chronic diseases, and soaring geriatric population. The number of trauma occurrences has skyrocketed lately on account of the upsurge in road accidents worldwide. In the U.S., approximately 1.7 mn people suffer from a traumatic brain injury every year, as per the statistics of the U.S. Centers for Disease Control and Prevention (CDC). Owing to its lackadaisical traffic security and overcrowded, poorly maintained roads, India sits at the top of the list of the highest number of road accidents. 

Each year, heart valve disease affects more than 5.0 mn people in the U.S., according to the American Heart Association (AHA). As a result, coronary angiography is expected to take the lead in the interventional cardiology procedures market. Other factors deemed responsible for the rise of interventional cardiology procedures include the towering incidences of structural heart disease and the resulting increasing usage of cardiac catheterization. The inflated growth of cardiovascular procedures could also be accredited to cardiac rhythm management device implantations including cardiac pacemaker procedures. 

Global Surgical Procedures Volume Market: Market Potential 

In a 2017 published statistical study presented in the journal Annals of Surgery, an attempt was made to determine the association between the total thyroidectomies per surgeon per year and risk of complications suffered by patients. However, even after a thorough research, the authors are still unclear about the definition of high-volume surgeon. Nevertheless, this study has played an important part in identifying a surgeon volume threshold which is vital for surgical education, quality improvement, and reimbursement and referral criteria. 

According to the study, the odds of complications reduced as surgeons performed more number of surgical procedures. After reviewing the hospital discharge data of 16,954 total thyroidectomy patients, the lowest percentage of complications was recorded with a surgeon performing 21 to 25 cases annually. 

Global Surgical Procedures Volume Market: Regional Outlook 

North America is prophesied to register a faster growth with the increase in C-section surgeries, minimally-invasive procedures, and elevating adoption and innovation of novel surgical technologies. The U.S. medical infrastructure, a decisive segment of North America, is predicted to accelerate its development while riding on an impressive hospital beds per capita statistic, surge in health care expenditure, and enormous health care infrastructure, and competitive reimbursement facilities. 

Holding a king’s share in the world surgical procedures volume market, Asia Pacific is envisaged to raise its banner with the spiraling number of cases related to neurological disorders, traumatic injuries, and cardiovascular diseases. The need for performing surgical procedures is anticipated to grow drastically in Asia Pacific as the population aging 65 years and above is foreseen to reach 857 mn by 2050. 

Europe is foretold to be a larger surgical procedures volume market as the number of orthopedic cases, cardiovascular diseases, traffic-related injuries, and fall injuries sees a tall rise. Growth opportunities could also birth in Brazil which roofs a high incidence of chronic diseases. 

Global Surgical Procedures Volume Market: Competitive Landscape 

Manufacturers of minimally-invasive surgical devices are prognosticated to rake in a higher revenue growth as patients look for procedures that entail shorter recovery time and hospital stay, lower number of post-surgery complications, and minimal incision. In this regard, MEMS-built pacemakers and da Vinci Xi Surgical System have gained a lot of popularity in the recent past.

About Us:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact Us:

Rohit Bhisey

Head Internet Marketing

Tel: +1-415-520-1050

Website: https://www.tmrresearch.com/

[chemicalsmaterial]

Global Cardiac Rhythm Management Market Scope

Global Cardiac Rhythm Management Market will exhibit a CAGR of 8% for the forecast period of 2022-2029

Market Analysis and Insights: Cardiac Rhythm Management

Cardiac rhythm management refers to a medical procedure of implanting such devices on the upper chest that help to monitor the fast and slow cardiac rhythm of an individual by using electrical pulses. Cardiac rhythm management devices are small battery powered medical devices that are connected to the heart resulting in monitoring and regulating the rhythm.

This past decade has been revolutionary for medical products and devices. Therefore, the cardiac rhythm management devices have been integrated with improved and advanced technologies such as implantable cardioverter defibrillators, and loop recorders. There is an increase in the popularity of cardiac rhythm management devices especially in the developing economies owing to the improving healthcare infrastructure.

This cardiac rhythm management market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiac rhythm management market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Get full report: https://www.databridgemarketresearch.com/reports/global-cardiac-rhythm-management-market

Cardiac Rhythm Management Market Scope and Market Size:

On the basis of product type, the cardiac rhythm management market is segmented into defibrillators, pacemakers and cardiac resynchronization therapy devices. 

On the basis of end user, the cardiac rhythm management market is segregated into home, ambulatory care, hospitals and others.

Cardiac Rhythm Management Market Country Level Analysis:

The countries covered in the cardiac rhythm management market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Get Sample Report here: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cardiac-rhythm-management-market

Major TOC of the Report:

Chapter One: Introduction

Chapter Two: Market Segmentation

Chapter Three: Market Overview  

Chapter Four: Executive Summary

Chapter Five: Premium Insight

Chapter Six: COVID-19 Impact on Global Cardiac Rhythm Management Market

 Get TOC here: https://www.databridgemarketresearch.com/toc/?dbmr=global-cardiac-rhythm-management-market

 Competitive Landscape & Cardiac Rhythm Management Market Share Analysis:

The cardiac rhythm management market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to cardiac rhythm management market.

 Key Players:

·        Medtronic,

·        Abbott,

·        Boston Scientific Corporation,

·        General Electric,

·        Koninklijke Philips N.V.,

·        BIOTRONIK SE & Co KG,

·        ZOLL Medical Corporation,

·        Cardiac Science Corporation,

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

[metiresearchinfo]

TOP 10 COMPANIES IN INTERVENTIONAL ONCOLOGY MARKET

Interventional oncology is an emerging and rapidly growing offshoot of interventional radiology, which emphasizes on the use of minimally-invasive procedures for the diagnosis, treatment, and palliative care for cancer patients. It uses image-guided technologies such as CT, fluoroscopy or ultrasound to target tumor lesions by making small puncture in the skin. Interventional oncology is generally meant for patients who are not able to respond positively towards the chemotherapy or radiation, or ones are unable to undergo surgery.

The global interventional oncology market is expected to grow at a CAGR of 7.7% from 2019 to 2025 to reach $1,506.3 million by 2025.

Here are the Top 10 Companies in Interventional Oncology :

Boston Scientific Corporation (U.S.)

Founded in 1979 and headquartered at Massachusetts, the U.S.; Boston Scientific Corporation (U.S.) is a developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company operates through three business segments namely Cardiovascular, Rhythm and Neuro, and MedSurg. The company provides interventional oncology products under the cardiovascular business segment. In cardiovascular business segment, the company provides technologies for diagnosing and treating coronary artery diseases, and other cardiovascular disorders including structural heart conditions under two sub-segments namely Interventional Cardiology and Peripheral Interventions. The Peripheral Interventions division offers devices used in peripheral angioplasty and peripheral vascular diseases along with interventional oncology products like peripheral embolization devices, microcatheters, and drainage catheters.

With its subsidiaries and strong network of distribution, the company has its presence in various regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The major subsidiaries of Boston Scientific Corporation are American Medical Systems Inc. (U.S.), Cameron Health, Inc. (U.S.), Boston Scientific Japan K.K. (Japan), and more.

Cook Medical LLC

Founded in 1963 and headquartered at Indiana, the U.S.; Cook Medical LLC is a manufacturer of minimally invasive medical devices. The company provides medical devices for 41 medical specialities including diagnostic radiology, endourology, gynecology, interventional radiology, obstetrics, and more. The company has two business divisions namely vascular and MedSurg. The company provides interventional oncology products under the vascular division. With its subsidiaries and strong network of distributors, the company has its presence across 135 countries.

The major subsidiaries of the company include Cook MyoSite Incorporated (U.S.) and Cook Urology (U.S.).

Merit Medical Systems, Inc.

Founded in 1987 and headquartered at Utah, the U.S.; Merit Medical Systems, Inc. is a manufacturer and marketer of disposable medical devices used across various therapeutic areas like cardiology, radiology, oncology, critical care, and endoscopy for the diagnosis, treatment therapy, and surgical intervention procedures. The company offer products for wide range of clinical area including interventional cardiology; electrophysiology; cardiac rhythm management; interventional oncology; pain management; and more. The company operates through two financial business segments namely cardiovascular and endoscopy. The company provides interventional oncology related products under the cardiovascular business segment.

With its subsidiaries and network of distribution, the company has its presence across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The major subsidiaries of the company include Merit Medical GmbH (Germany), BioSphere Medical, Inc. (U.S.), Merit Medical Austria GmbH (Austria).

C.R. Bard, Inc.

Founded in 1907 and headquartered at New Jersey, the U.S.; C. R. Bard, Inc. is a developer, manufacturer, and marketer of Vascular, Urology, Oncology, and Surgical products. The company focuses on the development of single-patient-use medical products for hospital procedures and is dedicated to pursuing technological innovations to offer superior clinical benefits while helping to reduce overall health care costs. The company markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. The company provides interventional oncology products under the segment BD Interventional.

With its subsidiaries and strong network of distribution, the company has its presence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. In December 2017, the company was acquired by Becton, Dickinson and Company (U.S.). This acquisition expanded the product offering of Becton, Dickinson, and Company across the care continuum and offered growth opportunities for both the companies in non-U.S. markets.

Profound Medical Corp.

Incorporated in 2008 and headquartered at Mississauga, Canada; Profound Medical Corp. is a developer and manufacturer of therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy of directional (inside-out) and focused (outside-in) ultrasound technology for incision-free ablation of diseased tissue. The company serves wide range of customers, which includes academic/university/clinical leadership hospitals as well as private clinics with access to MRI scanners. The company relies on its strategic partners, including Koninklijke Philips N.V. (the Netherlands) and Siemens AG (Germany), for lead generation and distribution of the capital units.

With its subsidiaries and strong network of distribution, the company has its presence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The major subsidiaries of the company include Profound Medical Inc. (Canada), Profound Medical Oy (Finland), Profound Medical GmbH (Germany), and Profound Medical (U.S.) Inc.

A report into the projected growth of the current Interventional Oncology Market by Meticulous Research® has produced some incredible forecasts for the industry. By 2025, it’s expected to have grown at a CAGR of 7.7%, reaching over $ 1.5 billion.

AngioDynamics, Inc.

Founded in 1988 and headquartered at New York, the U.S.; AngioDynamics, Inc. is engaged in designing, manufacturing, and selling of medical, surgical and diagnostic devices. These devices are used by healthcare professionals for the treatment of peripheral vascular disease, vascular access, oncology, and surgical settings. Moreover, these products are applicable for minimally invasive and image guided procedures. The company operates through three business segments namely Peripheral Vascular (“PV”), Oncology/Surgery (“OS”) and Vascular Access (“VA”). The company offers interventional oncology products under Oncology/Surgery business segment.

With its subsidiaries and strong network of distribution, the company has its presence across North America and other regions. The subsidiaries of the company are Navilyst Medical (U.S.), Vortex Medical, Inc. (U.S.), and AngioDynamics UK Ltd. (U.K.).

BTG plc

Incorporated in 1991 and headquartered at London, the U.K.; BTG plc is a healthcare company focusing on interventional medicine. The company provides products for the treatment of cancer, vascular conditions and severe emphysema. The company operates its business through three segments namely Interventional Medicine, Pharmaceuticals, and Licensing. The company offers interventional oncology products specifically for embolization, ablation, and cryoablation therapies under interventional medicine segment.

With its subsidiaries and strong network of distribution, the company has its presence across North America, Europe, Asia, and Australia. Biocompatibles International plc (U.K.), Protherics Inc. (U.S.), and Galil Medical Ltd (Israel) are few subsidiaries of the company.

Terumo Corporation

Founded in 1921 and headquartered at Tokyo, Japan; Terumo Corporation is engaged in manufacturing and selling of medical products and equipment, including pharmaceuticals, nutritional food supplement, blood bags, disposable medical devices, cardiovascular systems, vascular grafts, peritoneal dialysis products, blood glucose monitoring system, medical electronic, and digital thermometers. The company offers these products through three business segments namely Cardiac & Vascular Company, General Hospital Company, and Blood Management Company. The company provides interventional oncology products under Terumo Interventional Systems Division of Cardiac & Vascular Company business segment.

With its subsidiaries and strong network of distribution, the company has its presence across North America, Europe, Asia Pacific, and Rest of World. Terumo Medical Corporation (U.S.) and Terumo BCT, Inc. (U.S.) are few subsidiaries of the company.

Medtronic plc

Founded in 1949 and headquartered at Dublin, Ireland; Medtronic plc is engaged in developing and manufacturing medical technology, solutions, and services to reduce the pain with restoring health, and extending life for millions of people around the world. The company provides various medical products through four reportable segments namely Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The company offers interventional oncology products under minimally invasive therapies group business segment.

With its subsidiaries and strong network of distribution, the company has its presence across North America, Europe, Asia Pacific, and Rest of World. Covidien Ltd. (Ireland), Medtronic Limited (U.K.), Medtronic CoreValve LLC (U.S.) are few subsidiaries of the company.

HealthTronics, Inc.

Founded in 1989 and headquartered at Texas, the U.S.; HealthTronics, Inc. is engaged in providing integrated minimally invasive mobile technology-based products and services. The company offers lithotripsy, lasers, cryotherapy equipment, surgical nerve monitoring and microwave ablation as well as repair and maintenance services.

The company serves to hospitals and physicians. The company has healthcare facilities throughout the U.S. The company provides various products through its subsidiaries namely Endocare, Inc. (U.S.), Mobile Solutions, LLC (U.S.), and others.

Popular Mention: EDAP TMS S.A., Neuwave Medical, Inc., Sirtex Medical Limited, Trod Medical, Teleflex Incorporated, and IMBiotechnologies Ltd.

Authoritative Research on the Interventional Oncology Market – Global Opportunity Analysis and Industry Forecast (2019-2025)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

Recent financial performance

Key products

Significant company strategies

Partnerships and acquisitions

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.

[healthcare-market]

Surgical Procedures Volume Market to Reflect Impressive Growth Rate by 2023

A large number of companies are present in the surgical procedures volume market, making it fragmented. As this market holds tremendous potential of growth on account of rising advancements in technology in the healthcare sector as well as the growing demand for minimally invasive treatment options, a large number of companies are getting attracted to the market. Companies within the market are concentrating on expanding their reach and footprint buy networking with healthcare organizations. Players within the market are also investing extensively in research and development. Leading players with in the market are: Cutera Inc, Allergan PLC, Lumenis Ltd., and Cynosure Inc.

According to TMR, the global surgical procedures volume market is anticipated to reach 2.2 billion procedures by 2023. On the basis of geography, North America is the fastest growing Market and Asian Pacific is leading on account of the growing incidences of cardiovascular diseases, neurological disorders, traumatic injuries, and introduction of advanced surgical technologies. The market in North America is growing rapidly on account of the rising number of C-section surgeries, growing demand for minimally invasive surgical procedures, efficient and advanced health care infrastructure, and favourable reimbursement policies. In terms of volume, the gynaecological surgical procedures segment is leading in the market due to precise prognosis and treatment of disorders. The orthopaedic procedures segment, neurological segment, cardiovascular procedures, and dental segments are also lucrative.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1289

Rising Demand for Minimally Invasive Surgery Becoming a Trend Influencing Growth of Market

According to the lead author of the report, “the growing geriatric population is one of the key factors boosting surgical procedures.” The rising demand for minimally invasive procedures, advancements in technology in the medical sector, and rising investments for the improvement of the healthcare infrastructure are helping this market to grow. Rising incidences of trauma and the damage caused by accidents, street mishaps and the rising incidences of various chronic diseases are helping the market for surgical procedures to grow. The increasing spending capability of patients today as well as favourable reimbursement policies in various nations are also creating of favourable environment for the growth of the surgical procedures volume market.

Request for Analysis of COVID19 Impact on Surgical Procedures Volume Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1289

Unfavourable Reimbursement Policies to Affect Market’s Growth

On the other hand, the market will suffer on account of the high cost of surgeries, especially in underdeveloped regions. The lack of favourable reimbursement policies in some countries will also affect the market’s growth negatively. However, on a brighter note, the healthcare environment is changing and even the infrastructure in developing nations are improving due to efforts taken by government and several NGOs. This will help drive the growth of the global surgical procedures market in the coming years.

Buy now Surgical Procedures Volume Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1289&ltype=S

The data and information presented in this review is based on a TMR report, titled, “Surgical Procedures Volume Market (Procedures - Cardiac Rhythm Management Device Implantations (Cardiac Pacemaker Procedures, Implantable Cardioverter Defibrillators), Interventional Cardiology Procedures (Cardiac Catheterization, Coronary Revascularization, Coronary Angiography), Heart Transplantations, Neurosurgery Procedures (Craniotomy, Aneurysm Coil Embolization, CSF Drainage, CSF Shunt), Orthopedic Procedures (Joint Replacement Surgery (Knee Replacement, Hip Replacement, Shoulder Replacement), Ligament/Tendon Repair, Spine Surgery Market (Spinal Fusion ), Ophthalmic Procedures (Cataract Surgery, Glaucoma Surgery, Refractive Surgery), Gynecology Procedures, Hysterectomy, Laparoscopic Hysterectomy, Uterine Artery Embolization, Cesarean Section) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

More Trending Reports by Transparency Market Research:

Animal Blood Plasma Products and Derivatives Market Development in animal blood plasma products and derivatives has boosted adoption of animal blood plasma products and derivatives across numerous sectors in the food industry mainly for making pet food. Animal blood plasma products and derivatives are suitable alternative for the plant-extracted proteins for manufacturing pet food.

C-Arms Market The global X-ray market is responding positively to the new and improved C-arm systems or machines, with increase in uptake of technologically advanced C-arms. Additionally, digital C-arm systems are comparatively newer than analog C-arm systems, and have been able to make inroads into the C-arms market to become a market leader.

Thoracic Drainage Devices Market Chest tube thoracostomy or chest tube placement is a minimally-invasive procedure carried out to drain air, fluid, or blood from the thoracic space to prevent the lungs from collapsing. A chest tube is also called a thoracic catheter, chest drain, or intercostal drain. This thoracic catheter is inserted into the pleural space.

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Mr. Rohit Bhisey Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

[itssashasharma]

Cryotherapy Market : Future Of Cryotherapy Devices, It Is Creating Real Change In The Pain Management

Major Growth Drivers:

Growth in the cryotherapy market is primarily driven by factors such as the growing incidences of sports injuries, cardiac diseases, & cancers, and technological advancements in cryotherapy technology.

According to the new market research report ” Cryotherapy Market by Product (Cryosurgery Devices, Localized Cryotherapy Devices, Cryosaunas), Application (Surgical Application, Pain Management, Health & Beauty), End User (Hospitals & Specialty Clinics, Spas) – Global Forecast to 2024“, published by MarketsandMarkets™ , cryotherapy market is expected to grow from USD 206 million in 2019 to USD 319 million by 2024, at a CAGR of 9.1% during the forecast period.

Expected Revenue Growth:

[120 Pages Report] The cryotherapy market is expected to grow from USD 206 million in 2019 to USD 319 million by 2024, at a CAGR of 9.1% during the forecast period.

Accessories to Fuel the Growth of Cryotherapy Market :

Cryotherapy has become an important treatment option, mainly due to the various technological innovations and advancements in cryotherapy equipment over the years. Developments have been observed in various equipment, including cryosurgery units and accessories.

Browse in-depth TOC on “Cryotherapy Market“

78 – Tables31 – Figures121 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=33280524 Cryotherapy Market

The cryosurgery devices segment is projected to grow at the highest rate during the forecast period

By product, the cryotherapy market is segmented into cryosurgery devices (tissue contact probes, tissue spray probes, and epidermal & subcutaneous cryoablation devices), localized cryotherapy devices, and cryochambers & cryosaunas. The cryosurgery devices segment is expected to witness the fastest growth during the forecast period. Advantages offered by cryosurgery, such as fewer side effects and greater affordability, are increasing its adoption. Consequently, the demand for cryotherapy devices is also growing.

North America is expected to hold a dominant share in the cryotherapy market during the forecast period

North America held the largest share of the market in 2018 and is projected to continue to do so during the forecast period. Factors such as the growing popularity of cryotherapy, rising prevalence of cancer, increase in sports and physical activity-related injuries, and rising prevalence of CVDs are driving the North American cryotherapy market.

Key Market Players

The major vendors in the cryotherapy market include Medtronic (Ireland), Galil Medical (US), and CooperSurgical (US). These leading players offer an expansive product portfolio for cryoablation and have a wide geographic presence.

Recent Developments

In 2019, Medtronic collaborated with Phillips (Netherlands) to facilitate the sale of products on behalf of Philips to provide an innovative, integrated image guidance solution for cryoablation procedures, for the advance treatment of paroxysmal atrial fibrillation (PAF), a common heart rhythm disorder.

Kriosystem Life was the official supplier of cryotherapy devices for The World Games 2017, held in Wroclaw, Poland.

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=33280524 Cryotherapy Market

[riyamishh24]

ECG Monitoring Devices Industry Share 2021-2030: Business Development Analysis Report

ECG monitoring devices are medical devices used to detect heart defects such as arrhythmias and ischemia. These are also used to evaluate the function of a pacemaker or automatic implantable cardioverter-defibrillator as well as in early diagnosis of symptoms of various cardiovascular diseases such as angina, palpitations, dyspnea, and syncope. Technological advances in sensors have allowed the production of wearable devices capable of tracking and capturing long-term cardiac impulses. These systems may be used in out-of-hospital environments such as homes and public places, in the absence of traditional electrocardiogram (ECG) machines. For example, the Omron Healthcare offers HeartScan HCG-801 ECG Monitor is a cordless portable ECG monitor and shows heart rate (HR), rhythm, and ECG waveform on a high-resolution screen. Similarly, Zenicor-ECG, provided by Zenicor Medical Systems AB, is a handheld finger monitor, recorder and display device that makes atrial fibrillation (AF) and other cardiac arrhythmias simple and accurate to diagnose. The advent of such mobile, portable, and remote ECG monitoring devices will be one of the key market developments of the ECG devices responsible for growth of the ECG Monitoring Devices Industry Share over the forecast period.

Access the Full Report @ https://www.absolutemarketsinsights.com/reports/ECG-Monitoring-Devices-Market-2019-2027-494

The demand for ECG devices has propelled several technological advances in these devices, such as reduced size, increased portability and simplicity of use. The new generation ECG devices integrate advanced algorithms and different features for optimizing workflows, such as streamlined step-by-step operation, touch screen systems, and better connectivity with cardiovascular information systems (CVIS), electronic medical record (EMR), and ECG management systems. During patient monitoring procedures, ECG electrodes have undergone significant changes in design and interference over the years. Using conductive fiber, the ECG electrodes have been made smooth, flexible and breathable. In addition, textile electrodes do not cause the patient any pain or discomfort and provide a higher impedance to the skin-electrodes. During the forecast period, these technological advances are expected to fuel the ECG Monitoring Devices Industry Share growth at a CAGR of 10.3%.

The detailed research study provides qualitative and quantitative analysis of ECG monitoring devices market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Key Findings of the Report:

ECG     Monitoring Devices Industry Share is projected to reach US$ 15,673.7 Mn by  2030, growing at 10.3% CAGR during the forecast period

Due to the     availability of well-equipped instruments and the latest monitoring     software, hospitals accounted for the largest market share in 2018, since     most patients rely more on hospitals than other healthcare facilities

After     studying the global market, it was found that North America would account     for the largest market share of ECG monitoring devices over the forecast     period. Factors such as the high prevalence of cardiovascular diseases     (CVDs), increasing geriatric population and the adoption of     technologically advanced ECG devices will lead to the growth in demand for     ECG monitoring devices.

The major     market participants include GE Healthcare, Nihon Kohden, Schiller AG, Opto     Circuits, OSI Systems Fukuda Denshi Co Ltd., Johnson and Johnson, and     Medtronic, Koninklijke Philips N.V., Welch Allyn, CardiacMonitoring.com,     and Qardio, Inc. The key strategic approaches adopted by these players are     the new product development and mergers & acquisitions. For instance,     in April 2014, GE Healthcare launched a new MAC 2000 ECG resting program,     which aids to eliminate differences in ECG results and provides precise     information about the medical condition of the patients.

Global ECG Monitoring Devices Market:

By Type

Holter     Monitoring Systems

ECG Stress     Testing Systems

Resting     ECG Monitoring Systems

Event     Monitoring Systems

By End Users

Hospital     and Clinics

Ambulatory     Surgery Centers

Diagnostic     Centers

By Geography

North     America

Europe

Asia     Pacific

Middle     East & Africa

Latin     America

Contact Us: Company: Absolute Markets Insights Email id: sales@absolutemarketsinsights.com Phone: +91-740-024-2424 Contact Name: Shreyas Tanna Website: https://www.absolutemarketsinsights.com

[adityarana1687-blog]

Electrophysiology Devices Market Expected To Have An estimated Worth Of $12.2 Billion Valuation By 2026

The global electrophysiology devices market size is expected to reach USD 12.2 billion by 2026, according to a new report by Grand View Research, Inc. expanding at a CAGR of 11.70% over the forecast period. The demand for electrophysiology devices is expected to increase owing to growing old age population and frequent cardiac arrhythmias incidents. Adoption of ablation and diagnostics techniques among physicians has resulted in increased usage of the product in the past few years and is likely to drive market growth. Development of new devices such as Nanostim-dual-chamber leadless pacemaker is also anticipated to fuel demand in the market.

Cardiac ablation has gained popularity as the first-line treatment, rendering a 95% success rate for several rhythm disorders and is anticipated to be a key driving factor for growth. Diagnostic electrophysiology catheters are estimated to grow at high CAGR in the foreseeable future. Technological developments such as laser ablation, cryo-ablation, and ultrasound ablation, coupled with optimized mapping techniques are anticipated to augment market growth over the forecast period.

To request a sample copy or view summary of this report, click the link below: www.grandviewresearch.com/industry-analysis/electrophysiology-devices-market

Further Key Findings from the Study Suggest:

Electrophysiology diagnostic devices held a major share in the application segment in 2018. Collectively, cardiac monitors held the largest market share in electrophysiology diagnostic segment. The devices include Holter monitors, ECG monitors, and Insertable Cardiac Monitors (ICM). Growth can be attributed to increasing usage of digital and portable systems in the ambulatory setting and improving diagnostic interventional capabilities of healthcare consultants.

EP mapping and imaging systems are anticipated to grow rapidly during the forecast period. Technological improvements such as Optima IGS 320 and GE Healthcare’s Innova IGS 520 are projected to provide future opportunities for growth. These are dose efficient products and cardiac imaging systems that allow interventional cardiologist to perform compound interventional procedures with accuracy and ease.

Electrophysiology treatment devices include pacemakers, implantable cardioverter defibrillators (ICD) and catheters. Pacemakers emerged as the largest treatment devices segment in 2018 owing to rising prevalence of different types of arrhythmia among the population and extensive usage of cardiac rhythm management devices. However, rising costs related to the product, existence of strict regulations and accessibility of substitute therapies are anticipated to hamper the growth. Automated external defibrillators (AEDs) are expected to witness high growth rate during the forecast period attributed to increasing use in treating out-of-hospital cases of cardiac arrest.

North America held the largest market share in 2018 owing to a high patient base of cardiac arrhythmia resulting from unhealthy lifestyle habits. Increasing demand for the latest healthcare infrastructure and rising consumer awareness are anticipated to propel growth.

Asia-Pacific is a lucrative market owing to the high rate of unmet medical requirements leading to an increase in the number of patients. Rapid developments in healthcare infrastructure and increase in disposable income in emerging economies such as India and China are expected to provide new avenues and opportunities for companies to capitalize over the forecast period.

There are top 4 players who command around 60% of the electrophysiology devices market. Boston Scientific Corporation, Medtronic Plc., Abbot Laboratories, and Biosense Webster, Inc., is predominantly led by powerful product portfolios and significant brand recognition. Other players include Biotronik SE & Co. KG.

Grand View Research has segmented the global electrophysiology devices market based on medical condition, service and region:

Electrophysiology Devices Application Outlook (Revenue, USD Million; 2015 - 2026)

Treatment Devices

Diagnostic Devices

Implantable Cardioverter Defibrillators (ICDs)

Automated external defibrillators (AEDs)

Pacemakers

CRT-P

CRT-D

Catheters

Others

Holter Monitoring Devices

Diagnostic Electrophysiology Catheters

Electrocardiograph (ECG)

EP Mapping & Imaging Systems

Implantable cardiac monitors (ICM)

Others

Electrophysiology Devices Indication Outlook (Revenue, USD Million; 2015 - 2026)

Atrial Fibrillation (AF)

Supraventricular Tachycardia

Atrioventricular Nodal Re-entry Tachycardia (AVNRT)

Wolff-Parkinson-White Syndrome (WPW)

Bradycardia

Others

Electrophysiology Devices End-Use Outlook (Revenue, USD Million; 2015 - 2026)

Hospitals

Ambulatory Surgical Centers

Others

Electrophysiology Devices Region Outlook (Revenue, USD Million; 2015 - 2026)

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

U.S.

Canada

UK

Germany

France

Italy

Spain

Japan

China

India

Australia

Brazil

Mexico

Saudi Arabia

South Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

[market-research-future]

Wearable Heart Monitoring Devices Market Insights, Share and Growth By 2027

Wearable Heart Monitoring Devices Market   – Competitive Landscape The market appears to be fragmented and fiercely competitive owing to the presence of numerous large and small players, accounting for a substantial market share incorporating strategic initiatives such as partnership, acquisition, collaboration, expansion, and technology launch.  Significant investments are getting transpired to bring innovations into clinical trials. The growth potential demonstrated by the market is expected to attract several new entrants, which will intensify the competition in the market further.

Players are developing comprehensive, efficient, and state-of-the-art laboratories to develop cardiac monitoring and cardiac rhythm management devices that can provide tailor-made solutions based on the age, ailments, and other complications. With the advanced diagnostics and comprehensive rehabilitation schedule, these players ensure that every patient gets the best care at every stage of the cardiac management journey.

Major Players: Some of the leaders of the market include Kinetec Products UK Ltd. (South America), Medtronic (U.S.), Beurer GmbH (Europe), Briggs Healthcare (U.S.), Medisana AG (Europe), Polar Electro (Europe), Koninklijke Philips N.V. (Europe), SUUNTO (Europe), and Garmin Ltd. (Europe).

Market Highlights: The Wearable Heart Monitoring Devices Market is accruing pervasively mainly due to the growing rate of cardiovascular disorders, worldwide. Currently, the world is witnessing an increasing number of issues related to heart diseases and cardiac disorder cases. Unfortunately, the figure is growing every year. Although a number of procedures and innovative therapies are there in the market, incidents of occurring these diseases are rising continuously and are becoming paramount concerns. Such factors are increasing the growth the wearable heart monitoring devices market, globally.

Accrediting the growth of this fiercely ascending market, Market Research Future (MRFR) in its recently published study report asserts that the global wearable heart monitoring devices market will continue to grow by 2023, registering approximately 9.86% CAGR during the forecast period (2017-2023).

Growing technological advancements in the field of heart care drive market growth, Global wearable heart monitoring devices market are heading with the pervasively rising number of patients suffering from arterial diseases. Moreover, the increasing number of the patient suffering from obesity and diabetes along with the changing lifestyle has been supporting the expansion of the Wearable Heart Monitoring Devices market.

On the other hand, factors such as the stringent government regulations and unfavorable reimbursement policies are obstructing the market growth in some countries, acting as a headwind. Also, the lack of expert healthcare professionals is estimated to impede the growth of the market over the forecast period.

Wearable Heart Monitoring Devices Market – Segmentations

MRFR has segmented the analysis into five key dynamics for better understanding:

By Product:  Electric Pulse Based Product (chest straps, chest patches and others) and Optical Technology Based (smart watches, earphones, and others.)

By Type:  Chargeable, Non-chargeable, and Bluetooth Enabled among others.

By Application:  Healthcare and Consumer Market among others.

By End-user:  Hospitals, Retail Pharmacies, and Academic Institutes among others.

By Regions:  Europe, North America, APAC and the Rest-of-the-World.

Wearable Heart Monitoring Devices Market   – Geographical Analysis North America accounts for the global leader for the wearable heart monitoring devices market. Factors positively impacting market growth include the increasing prevalence of cardiovascular diseases, hypertension, and obesity issues that are leading to heart diseases & disorders and the rising geriatric population.  The market is continually growing due to the growing number of patients suffering from major/minor heart issues.

Additionally, increasing government initiatives and funding for research, rising demand for technologically advanced cardiac monitoring and cardiac rhythm management devices, and developments in advanced medical treatment options are substantiating the market growth.

The Wearable Heart Monitoring Devices Market  in the European region accounts for the second-largest market. Owing to the increasing healthcare expenditure, availability of advanced treatment facilities, and government initiatives, the European region is likely to register a striking CAGR during the review period. Increasing cardiovascular issues are contributing to the market growth in the region, becoming paramount concerns.

The Wearable Heart Monitoring Devices Market  in the Asia Pacific region is rapidly emerging as a promising market. The increasing number of aging populaces alongside the prevalence of cardiac disorders are driving the market in the region, growing at an alarming rate. Simultaneously, other dominant factors such as the faster adoption of healthcare technology, government initiatives to improve the quality of healthcare, favorable insurance, and reimbursement policies are fostering the growth of the APAC market.

Additionally, eminent key players are increasingly setting up their manufacturing plants in some of the APAC countries such as China, Singapore, Japan, Australia, and Korea which, in turn, is propelling the market growth of wearable heart monitoring devices in this region.

Industry/Innovations/Related News: November 14, 2018 – Withings SAS (formerly Nokia Health – France), a health ecosystem of connected devices & apps announced the latest addition to its product line with the Pulse HR, a connected wearable that can track a user’s heart rate using photoplethysmography (PPG) sensors that can measure pulse in 10-minute intervals while offering continuous heart rate measurements for each workout session.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/wearable-heart-monitoring-device-market-4714

Browse Related Reports at:

Healthcare Artificial Intelligence (AI) Market Size, Global Report, Trends, Industry Analysis by 2027

Human Insulin Market by Type, Share, Growth and Analysis – 2027 | MRFR

Durable Medical Equipment Market Size, Share, Trends and Industry Analysis to 2027

[marketstudyreport]

Cardiac Rhythm Management Devices Market 2025: Trends, Opportunities, Challenges & Leading Key Players Review

26th April 2021 – The global cardiac rhythm management (CRM) devices market size is projected to reach at USD 32.4 billion by 2025. The CRM devices market is subject to witness substantial growth due to numerous awareness programs and schemes by regional governments in emerging and developed economies. Growing occurrence of cardiovascular diseases (CVDs), supportive legislative policies, and critical advancements in technology are attributing to the progress of the market in forecast period. Though, initial cost associated with implementation of cardiac rhythm management (CRM) devices and lack of awareness in rural parts across the globe is limiting the market expansion of cardiac rhythm management (CRM) devices market. The CRM devices market is expected to grow at a 7.5% CAGR during the forecast period.

Cardiac rhythm management (CRM) devices are considered as most viable option for the treatment for the patients suffering through diseases like arrhythmias. The recent advancement in cardiac resynchronization therapies (CRTs) and devices are driving the market growth. Alongside, the rising use of the implantable cardioverter-defibrillators (ICDs) and its applications alongside their integration with pacemakers in order to improve the product’s life cycle are playing crucial part for treatment of heart diseases. The progress of the cardiac rhythm management (CRM) devices industry is also attributed to the factors such as need for external defibrillators due to growing awareness of its use and increasing occurrence of diseases related to the sudden cardiac arrest (SCA).

Access Cardiac Rhythm Management (CRM) Devices Market Report with TOC @ https://www.millioninsights.com/industry-reports/cardiac-rhythm-management-crm-devices-market

Cardiac rhythm management (CRM) is a procedure that involves the treatment of arrhythmias (heart rhythm disorders). Arrhythmias are responsible for causing number of problems for patients, such as palpitations, anxiety and dizziness, that may lead to blackouts and cardiac arrest as well. The cardiac rhythm management (CRM) term is loosely based on treatments involving implanted electronic devices similar to pacemakers and defibrillators. Cardiac rhythm management (CRM) devices are mainly classified into three common types such as pacemakers, implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT). Pacemakers are used for the treatment of slow heart rates or attacks in dire situation where heart stop functioning, leading to dizziness, blackouts, or even death. They provide small amount of electrical impulses that may trigger the heartbeat.

The other type of cardiac rhythm management (CRM) devices such as implantable cardioverter defibrillator (ICD) is implemented in case of sudden cardiac arrests because of the faster or chaotic beating in the central pumping chamber i.e. ventricular tachycardia. In such scenarios, implantable cardioverter defibrillator (ICD) creates a shockwave in order to restore the normal heart rhythm, the shock is created automatically within seconds. The use of cardiac resynchronization therapy (CRT) devices allows proper functioning of poorly coordinated ventricles such as central pumping chambers that can lead to heart failure. CRT devices are responsible for pacing the left ventricle involving central pumping chamber from both sides of the ventricles. This provides relaxation for patients from symptoms and boosts their morality.

The use of ICDs and CRT devices offers immediate and long-term solution in comparison with the bradycardia pacemakers. Implanting both CRT and ICD devices on patients is vital for successful treatment. The applications of these devices aids to amplify the health outcomes and ensures welfare for patients by designing devices to carry out the highly efficient therapy, at times evaluating and reducing system complications while utilizing precise device diagnostic data for successful treatment. The market is divided into regional market segment such as North America, Europe, Asia-Pacific, Latin America and Africa. North America has shown major growth in recent years owing to the rise adoption of latest technologies in healthcare sector and existence well-established healthcare infrastructure. Asia-Pacific market is predicted to hold higher share in the cardiac rhythm management (CRM) devices market with massive growth in forecast period.

Countries such as India, China and Singapore are leading the Asia-Pacific market with growing penetration of health insurance in emerging economies and generating substantial investment by multinational market players due to potential opportunities in the region. The key players in the cardiac rhythm management (CRM) devices industry are Medtronic Ltd., BIOTRONIK Incorporations, Boston Scientific Co., St. Jude Medical Co., ZOLL Medical Co., and Philips N.V.

Request a Sample Copy of Cardiac Rhythm Management (CRM) Devices Market Report @ https://www.millioninsights.com/industry-reports/cardiac-rhythm-management-crm-devices-market/request-sample